Gilead Sciences

Gilead Sciences is one of the...

• Forbes Global 2000 (#206);
• Fortune 500 (#129);
• Russell 3000;
• S&P 500.

Gilead Sciences is a company listed under the stock ticker GILD (US).

Gilead Sciences has a direct presence in 7 countries.

Gilead Sciences has 7 subsidiaries including Gilead Sciences Canada, Gilead Sciences EMEA and Gilead Sciences Germany.

They are in:

• Pharmaceuticals63%
• Biotechnology25%
• Other13%

Acquisition, funding and merger involving Gilead Sciences.

• Gilead Sciences has announced the acquisition of MiroBio  (posted on August 5 2022).

View the org chart displaying its 71 main executives

Most searched biographies at Gilead Sciences

• Daniel O'Day, Chairman of the Board and Chief Executive Officer
• Sandra Horning, Director
• Kelly Kramer, Director

Popular executive movements at Gilead Sciences

• Deborah Telman will join the company as Executive Vice President, Corporate Affairs and General Counsel on Aug. 1, 2022  (posted on July 12 2022).
• Brett Pletcher, Executive Vice President, General Counsel and Chief Compliance Officer, will retire on Jul. 31, 2022  (posted on July 12 2022).

Create your alert
to follow the executive moves at Gilead Sciences.

Gilead Sciences has 1,922 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Roche (Switzerland).

Popular M&A news in Pharmaceuticals

• Ambrx has just announced a $78 Million fundraising (posted on March 13 2023).
• Mayne Pharma US and Dr. Reddy's have announced they will merge  (posted on February 28 2023)..
• Fusion Pharma has just announced a $60 Million fundraising (posted on February 16 2023).

Popular contacts in Pharmaceuticals

• Danilo Cicmil - Supervisory Board Member at Galenika
• Stéphane Bancel - Director, President and Founding Chief Executive Officer at Moderna
• Rongrong Pan - Vice President and Chief Financial Officer at Sciclone Pharmaceuticals

Learn more about the Pharmaceuticals industry >

Press releases by Gilead Sciences

• Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities
• Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
• Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
• Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV
• Kite Completes Acquisition of Tmunity
• Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients
• Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies
• Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer
• Christi Shaw to Depart Gilead and Kite Leadership End of Q1
• Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
• View more press releases Close

Social media about Gilead Sciences

• Gilead Sciences on Wikipedia, Google News & Yahoo Finance
• Gilead Sciences on LinkedIn, Twitter & YouTube

Contact by email its executives including Jeffrey Bluestone

Call Gilead Sciences at +1 650...

View the org chart

Register to receive your alert

Report an error